CORRECTION NOTICE

Nat. Biotechnol. 33, 187–197 (2015)

GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

Shengdar Q Tsai, Zongli Zheng, Nhu T Nguyen, Matthew Liebers, Ved V Topkar, Vishal Thapar, Nicolas Wyvekens, Cyd Khayter, A John Iafrate, Long P Le, Martin J Aryee & J Keith Joung

In the version of this supplementary file originally posted online, the primer labels 'Nuclease_off_+_GSP1' and 'Nuclease_off_-_GSP1' were switched in Supplementary Table 4, and the discovery thermocycling conditions were missing from the Supplementary Methods. The errors have been corrected in this file as of 25 June 2015.

Supplementary Fig. 1 Detailed schematic overview of GUIDE-Seq and AMP-based sequencing for validation of dsODN insertions and indel mutations



Details for both protocols can be found in Supplementary Methods.

Supplementary Fig. 2 GUIDE-Seq-based identification of DSBs induced by RGNs directed by full-length gRNAs




FANCF: chr6_143382085_101
FANCF: chr10_37953199_77
FANCF: chr10_43410031_524
FANCF: chr10_73463136_78
FANCF: chr11_22647338_4816
FANCF: chr16_49671025_4
FANCF: chr17_78923978_150
FANCF: chr18_8707527_2099
FANCF: chrX_86355179_125
HEK293_sgRNA1: chr1_201992440_781
HEK293_sgRNA1: chr8_21121524_116
HEK293_sgRNA1: chr8_48879626_7
HEK293_sgRNA1: chr9_110103704_1975
HEK293_sgRNA1: chr9_129621087_37
HEK293_sgRNA1: chr10_123094946_265
HEK293_sgRNA1: chr13_31633478_4
HEK293_sgRNA1: chr19_10362662_13
HEK293_sgRNA1: chr22_43689599_3
HEK293_sgRNA1: chr22_47970524_6
HEK293_sgRNA2: chr4_90522183_99
HEK293_sgRNA2: chr5_87240613_1670
HEK293_sgRNA2: chr10_87125365_4
HEK293_sgRNA3: chr1_47005705_136
HEK293_sgRNA3: chr7_66968041_306
HEK293_sgRNA3: chr9_110184636_2074
HEK293_sgRNA3: chr10_131593121_2
HEK293_sgRNA3: chr15_79749930_327
HEK293_sgRNA3: chrX_114764149_10
HEK293_sgRNA4: chr1_1956152_8
HEK293_sgRNA4: chr1_12259809_7
HEK293_sgRNA4: chr1_44397931_6
HEK293_sgRNA4: chr1_150530478_4



HEK293_sgRNA4: chr1_160016384_12
HEK293_sgRNA4: chr1_171018460_361
HEK293_sgRNA4: chr1_201067377_163
HEK293_sgRNA4: chr1_204463911_33
HEK293_sgRNA4: chr2_25348467_67
HEK293_sgRNA4: chr2_45247404_116
HEK293_sgRNA4: chr2_96016389_10
HEK293_sgRNA4: chr2_98637989_8
HEK293_sgRNA4: chr2_152827915_91
HEK293_sgRNA4: chr2_241640853_24
HEK293_sgRNA4: chr3_10418955_201
HEK293_sgRNA4: chr3_23651527_40
HEK293_sgRNA4: chr3_49055364_165
HEK293_sgRNA4: chr3_51725451_316
HEK293_sgRNA4: chr3_52035832_60
HEK293_sgRNA4: chr3_52321883_47
HEK293_sgRNA4: chr3_53375995_192
HEK293_sgRNA4: chr3_66705574_8
HEK293_sgRNA4: chr3_130508524_12
HEK293_sgRNA4: chr3_142741805_10
HEK293_sgRNA4: chr3_184289225_62
HEK293_sgRNA4: chr3_195550472_3
HEK293_sgRNA4: chr4_56815199_240
HEK293_sgRNA4: chr4_82962294_10
HEK293_sgRNA4: chr4_183980137_22
HEK293_sgRNA4: chr5_1832937_99
HEK293_sgRNA4: chr5_3606830_36
HEK293_sgRNA4: chr5_54469282_22
HEK293_sgRNA4: chr5_96338759_29
HEK293_sgRNA4: chr5_139284046_5
HEK293_sgRNA4: chr5_177676325_64
HEK293_sgRNA4: chr6_10416021_6


HEK293_sgRNA4: chr6_13588034_6
HEK293_sgRNA4: chr6_33611484_22
HEK293_sgRNA4: chr6_36761680_83
HEK293_sgRNA4: chr6_40975969_6
HEK293_sgRNA4: chr6_41374185_4
HEK293_sgRNA4: chr6_51500472_32
HEK293_sgRNA4: chr6_158452389_8
HEK293_sgRNA4: chr6_160517881_789
HEK293_sgRNA4: chr7_139631_7
HEK293_sgRNA4: chr7_1397398_179
HEK293_sgRNA4: chr7_29233958_6
HEK293_sgRNA4: chr7_54561437_656
HEK293_sgRNA4: chr7_95064070_8
HEK293_sgRNA4: chr7_110143150_297
HEK293_sgRNA4: chr7_134872031_198
HEK293_sgRNA4: chr7_139244407_90
HEK293_sgRNA4: chr7_150498859_5
HEK293_sgRNA4: chr7_157443385_12
HEK293_sgRNA4: chr8_20854500_13
HEK293_sgRNA4: chr8_119227145_123
HEK293_sgRNA4: chr8_144781301_37
HEK293_sgRNA4: chr9_5020590_17
HEK293_sgRNA4: chr9_74103954_17
HEK293_sgRNA4: chr9_111305521_12
HEK293_sgRNA4: chr9_133039176_194
HEK293_sgRNA4: chr9_136602370_61
HEK293_sgRNA4: chr9_138465751_23
HEK293_sgRNA4: chr9_139522900_66
HEK293_sgRNA4: chr9_140205577_30
HEK293_sgRNA4: chr10_13692637_712
HEK293_sgRNA4: chr10_73435247_32
HEK293_sgRNA4: chr10_77103119_1097


HEK293_sgRNA4: chr10_126694874_1375

HEK293_sgRNA4: chr10_126752486_78

HEK293_sgRNA4: chr12_48045645_18

HEK293_sgRNA4: chr12_53453556_49

HEK293_sgRNA4: chr12_54977735_2

HEK293_sgRNA4: chr12_55427953_13

HEK293_sgRNA4: chr12_113935461_19

HEK293_sgRNA4: chr12_131356926_16

HEK293_sgRNA4: chr13_27629410_664

HEK293_sgRNA4: chr13_39262929_981

HEK293_sgRNA4: chr13_41969958_27

HEK293_sgRNA4: chr13_48891654_7

HEK293_sgRNA4: chr13_88900992_108

HEK293_sgRNA4: chr14_21993454_49

HEK293_sgRNA4: chr14_24740271_116

HEK293_sgRNA4: chr14_63796588_10

HEK293_sgRNA4: chr14_88773031_119

HEK293_sgRNA4: chr14_95761249_31

HEK293_sgRNA4: chr15_34081545_39

HEK293_sgRNA4: chr15_41044241_1002

HEK293_sgRNA4: chr15_60790562_4

HEK293_sgRNA4: chr15_71686928_11

HEK293_sgRNA4: chr15_101714924_20

HEK293_sgRNA4: chr16_1029978_24

HEK293_sgRNA4: chr16_28266968_53

HEK293_sgRNA4: chr16_50300347_536

HEK293_sgRNA4: chr16_67742859_8

HEK293_sgRNA4: chr16_88716134_192

HEK293_sgRNA4: chr16_89469251_21

HEK293_sgRNA4: chr17_176301_352

HEK293_sgRNA4: chr17_1007831_5

HEK293_sgRNA4: chr17_16982385_33



HEK293_sgRNA4: chr17_29815563_89
HEK293_sgRNA4: chr17_38478447_7
HEK293_sgRNA4: chr17_64544877_25
HEK293_sgRNA4: chr17_72251122_78
HEK293_sgRNA4: chr17_75429279_644
HEK293_sgRNA4: chr18_37194557_249
HEK293_sgRNA4: chr19_1295086_127
HEK293_sgRNA4: chr19_12721963_4
HEK293_sgRNA4: chr19_15302535_10
HEK293_sgRNA4: chr19_33382080_2020
HEK293_sgRNA4: chr19_38616186_982
HEK293_sgRNA4: chr19_41220525_445
HEK293_sgRNA4: chr19_46887173_227
HEK293_sgRNA4: chr20_1151854_539
HEK293_sgRNA4: chr20_22805414_4
HEK293_sgRNA4: chr20_24376056_38
HEK293_sgRNA4: chr20_31349772_1054
HEK293_sgRNA4: chr20_37471343_241
HEK293_sgRNA4: chr20_45343010_650
HEK293_sgRNA4: chr20_60010563_2475
HEK293_sgRNA4: chr20_60080554_102
HEK293_sgRNA4: chr20_60174570_12
HEK293_sgRNA4: chr20_60895671_369
HEK293_sgRNA4: chr20_61810738_59
HEK293_sgRNA4: chr21_46875425_9
HEK293_sgRNA4: chr22_27650937_6
HEK293_sgRNA4: chr22_30130865_138
HEK293_sgRNA4: chr22_35746282_13
HEK293_sgRNA4: chr22_41620072_3
HEK293_sgRNA4: chr22_43768275_17
HEK293_sgRNA4: chr22_49132903_8
HEK293_sgRNA4: chr22_51011687_7



HEK293_sgRNA4: chrX_123096978_8
HEK293_sgRNA4: chrX_152805652_5
RNF2: chr1_185056773_6643
VEGFA_site1: chr1_99347651_819
VEGFA_site1: chr1_233157353_58
VEGFA_site1: chr3_125633992_4
VEGFA_site1: chr3_128284321_16
VEGFA_site1: chr3_195871264_11
VEGFA_site1: chr4_8453802_24
VEGFA_site1: chr5_7067158_115
VEGFA_site1: chr5_32945275_246
VEGFA_site1: chr5_56172097_50
VEGFA_site1: chr6_14316373_241
VEGFA_site1: chr6_43737297_2685
VEGFA_site1: chr11_67574261_7
VEGFA_site1: chr11_117481208_14
VEGFA_site1: chr12_1988076_375
VEGFA_site1: chr12_131690198_597
VEGFA_site1: chr13_26202811_6
VEGFA_site1: chr15_65637537_3237
VEGFA_site1: chr16_8763213_5
VEGFA_site1: chr17_39796328_1935
VEGFA_site1: chr17_47317539_324
VEGFA_site1: chr22_19698463_47
VEGFA_site1: chr22_37215275_249
VEGFA_site2: chr1_875337_135
VEGFA_site2: chr1_1294273_19
VEGFA_site2: chr1_23762251_13
VEGFA_site2: chr1_52217921_13
VEGFA_site2: chr1_151031887_625
VEGFA_site2: chr1_178738727_4
VEGFA_site2: chr1_237195681_25


VEGFA_site2: chr2_11699964_95
VEGFA_site2: chr2_12744775_414
VEGFA_site2: chr2_24857593_87
VEGFA_site2: chr2_43608538_13
VEGFA_site2: chr2_85515492_3
VEGFA_site2: chr2_101437467_22
VEGFA_site2: chr2_105990827_45
VEGFA_site2: chr2_129244202_108
VEGFA_site2: chr2_150391412_17
VEGFA_site2: chr2_170573355_98
VEGFA_site2: chr2_221535832_23
VEGFA_site2: chr2_223731497_7
VEGFA_site2: chr2_242214606_1549
VEGFA_site2: chr3_13187302_8
VEGFA_site2: chr3_31458658_256
VEGFA_site2: chr3_38141265_15
VEGFA_site2: chr3_49850177_23
VEGFA_site2: chr3_55857495_4
VEGFA_site2: chr3_65075658_2
VEGFA_site2: chr3_140398800_111
VEGFA_site2: chr4_1496257_92
VEGFA_site2: chr4_7329546_87
VEGFA_site2: chr4_8841917_235
VEGFA_site2: chr4_38537627_1054
VEGFA_site2: chr4_143767373_34
VEGFA_site2: chr5_6715118_1925
VEGFA_site2: chr5_14457504_122
VEGFA_site2: chr5_122565828_3
VEGFA_site2: chr5_132860375_29
VEGFA_site2: chr5_139028256_65
VEGFA_site2: chr5_156321140_59
VEGFA_site2: chr5_170878070_71


VEGFA_site2: chr6_26470622_4
VEGFA_site2: chr6_31462826_8
VEGFA_site2: chr6_36853825_12
VEGFA_site2: chr6_41543448_15
VEGFA_site2: chr6_43337337_15
VEGFA_site2: chr6_43738562_540
VEGFA_site2: chr6_110521033_4
VEGFA_site2: chr7_1478608_9
VEGFA_site2: chr7_44253556_17
VEGFA_site2: chr7_50765529_65
VEGFA_site2: chr7_95319677_179
VEGFA_site2: chr7_101150798_15
VEGFA_site2: chr7_104933955_135
VEGFA_site2: chr7_130791581_10
VEGFA_site2: chr8_18041545_160
VEGFA_site2: chr8_37251195_9
VEGFA_site2: chr8_39839086_17
VEGFA_site2: chr8_122367963_15
VEGFA_site2: chr8_137500402_5
VEGFA_site2: chr8_144822961_728
VEGFA_site2: chr8_145008405_603
VEGFA_site2: chr9_2666738_12
VEGFA_site2: chr9_27338874_767
VEGFA_site2: chr9_33202624_3
VEGFA_site2: chr9_37465365_18
VEGFA_site2: chr9_37990376_4
VEGFA_site2: chr9_100732585_12
VEGFA_site2: chr9_100931292_3
VEGFA_site2: chr9_103599649_1178
VEGFA_site2: chr9_126138181_128
VEGFA_site2: chr9_130663087_10
VEGFA_site2: chr9_131706582_25


VEGFA_site2: chr9_139440844_202
VEGFA_site2: chr9_140263445_31
VEGFA_site2: chr10_72538217_75
VEGFA_site2: chr10_102821517_32
VEGFA_site2: chr10_116294256_704
VEGFA_site2: chr10_133956644_126
VEGFA_site2: chr10_135149947_446
VEGFA_site2: chr11_374666_252
VEGFA_site2: chr11_2686249_40
VEGFA_site2: chr11_12308933_121
VEGFA_site2: chr11_13948370_246
VEGFA_site2: chr11_31817483_483
VEGFA_site2: chr11_32184484_16
VEGFA_site2: chr11_45796055_29
VEGFA_site2: chr11_46141855_336
VEGFA_site2: chr11_61321439_19
VEGFA_site2: chr11_63391090_362
VEGFA_site2: chr11_65479769_7
VEGFA_site2: chr11_67351523_27
VEGFA_site2: chr11_71948805_919
VEGFA_site2: chr11_76495788_627
VEGFA_site2: chr11_83433600_65
VEGFA_site2: chr11_133777457_14
VEGFA_site2: chr12_3200977_14
VEGFA_site2: chr12_26025095_123
VEGFA_site2: chr12_57604331_6
VEGFA_site2: chr12_86681297_7
VEGFA_site2: chr12_123893673_3
VEGFA_site2: chr12_132529366_7
VEGFA_site2: chr12_133287148_10
VEGFA_site2: chr13_26626241_365
VEGFA_site2: chr13_100546988_303



VEGFA_site2: chr13_114795514_2
VEGFA_site2: chr14_90403321_21
VEGFA_site2: chr14_104601208_2
VEGFA_site2: chr15_33286107_391
VEGFA_site2: chr15_78857725_24
VEGFA_site2: chr16_56963429_1107
VEGFA_site2: chr16_57974238_30
VEGFA_site2: chr16_67289447_14
VEGFA_site2: chr16_69166711_7
VEGFA_site2: chr16_82734581_278
VEGFA_site2: chr16_85338205_37
VEGFA_site2: chr17_4358752_803
VEGFA_site2: chr17_7147480_4
VEGFA_site2: chr17_16954852_141
VEGFA_site2: chr17_40044757_791
VEGFA_site2: chr17_46103848_21
VEGFA_site2: chr17_55740529_31
VEGFA_site2: chr17_58404869_16
VEGFA_site2: chr17_62167053_29
VEGFA_site2: chr17_65632990_35
VEGFA_site2: chr17_72656677_6
VEGFA_site2: chr17_79881149_13
VEGFA_site2: chr18_21359559_357
VEGFA_site2: chr18_55101360_18
VEGFA_site2: chr19_1028249_9
VEGFA_site2: chr19_1494330_3
VEGFA_site2: chr19_13122188_291
VEGFA_site2: chr19_14142975_192
VEGFA_site2: chr19_18131314_4
VEGFA_site2: chr19_18633483_9
VEGFA_site2: chr19_36759134_24
VEGFA_site2: chr19_42806801_32


VEGFA_site2: chr19_45324581_4
VEGFA_site2: chr19_45952054_74
VEGFA_site2: chr19_51915519_12
VEGFA_site2: chr20_10913961_138
VEGFA_site2: chr20_35991133_18
VEGFA_site2: chr20_62575817_9
VEGFA_site2: chr21_46703222_9
VEGFA_site2: chr22_23260204_3
VEGFA_site2: chr22_40102400_36
VEGFA_site2: chr22_43684495_25
VEGFA_site2: chr22_45134894_75
VEGFA_site2: chr22_47511254_52
VEGFA_site2: chr22_50884803_704
VEGFA_site2: chrX_118865483_63
VEGFA_site2: chrX_129040641_263
VEGFA_site2: chrX_149932528_330
VEGFA_site2: chrX_152837128_37
VEGFA_site3: chr1_32738763_3
VEGFA_site3: chr1_47690893_3
VEGFA_site3: chr1_48305038_17
VEGFA_site3: chr1_181557203_5
VEGFA_site3: chr2_18696224_9
VEGFA_site3: chr2_73317048_122
VEGFA_site3: chr2_177463426_33
VEGFA_site3: chr2_230506241_20
VEGFA_site3: chr3_5104940_22
VEGFA_site3: chr3_71632809_215
VEGFA_site3: chr3_193993884_1315
VEGFA_site3: chr4_58326607_97
VEGFA_site3: chr4_62067619_29
VEGFA_site3: chr5_29367379_103
VEGFA_site3: chr5_89440969_2559


VEGFA_site3: chr5_115434675_2200

VEGFA_site3: chr5_130857602_35

VEGFA_site3: chr6_43737470_2440

VEGFA_site3: chr6_144458290_4

VEGFA_site3: chr6_157078327_37

VEGFA_site3: chr7_51294278_17

VEGFA_site3: chr8_22932503_111

VEGFA_site3: chr8_48997805_82

VEGFA_site3: chr8_67579427_6

VEGFA_site3: chr8_143890826_17

VEGFA_site3: chr9_18733635_149

VEGFA_site3: chr9_23824554_643

VEGFA_site3: chr9_139223458_4

VEGFA_site3: chr10_5749657_41

VEGFA_site3: chr10_98760588_1437

VEGFA_site3: chr10_130228353_24

VEGFA_site3: chr11_68851138_1535

VEGFA_site3: chr11_75147779_18

VEGFA_site3: chr11_79178522_32

VEGFA_site3: chr12_6937055_61

VEGFA_site3: chr13_114882999_83

VEGFA_site3: chr14_58118445_37

VEGFA_site3: chr14_62078773_1170

VEGFA_site3: chr14_65569159_3125

VEGFA_site3: chr14_74353496_790

VEGFA_site3: chr14_106029031_199

VEGFA_site3: chr16_12264612_6

VEGFA_site3: chr16_73585927_13

VEGFA_site3: chr16_74898120_11

VEGFA_site3: chr16_84032646_26

VEGFA_site3: chr17_33323268_17

VEGFA_site3: chr17_78954440_11



Start sites of GUIDE-Seq reads mapped back to the genome enable localization of the DSB to within a few base pairs. Mapped reads for the on- and off-target sites of the ten RGNs directed by full-length gRNAs we assessed by GUIDE-Seq are shown. In all cases, the target site sequence is shown with the 20 bp protospacer sequence to the left and the PAM sequence to the right on the x-axis.

Supplementary Fig. 3 Chromosome ideograms of CRISPR/Cas9 on- and off-target sites for all ten RGNs evaluated by GUIDE-Seq



Supplementary Fig. 4 Histogram plots of mapped indel mutations for six RGN on-target and off-target sites




Round3_nuclease_VEGFA_site1 chr17_39796328_1935
Round3_nuclease_VEGFA_site1 chr17_47317539_324
Round3_nuclease_VEGFA_site2 chr1_875337_135
Round3_nuclease_VEGFA_site2 chr2_11699964_95
Round3_nuclease_VEGFA_site2 chr2_12744775_414
Round3_nuclease_VEGFA_site2 chr3_55857495_4
Round3_nuclease_VEGFA_site2 chr3_140398800_111
Round3_nuclease_VEGFA_site2 chr4_1496257_92
Round3_nuclease_VEGFA_site2 chr4_7329546_87
Round3_nuclease_VEGFA_site2 chr4_8841917_235
Round3_nuclease_VEGFA_site2 chr4_38537627_1054
Round3_nuclease_VEGFA_site2 chr5_6715118_1925
Round3_nuclease_VEGFA_site2 chr5_132860375_29
Round3_nuclease_VEGFA_site2 chr6_26470622_4
Round3_nuclease_VEGFA_site2 chr6_36853825_12
Round3_nuclease_VEGFA_site2 chr7_50765529_65
Round3_nuclease_VEGFA_site2 chr7_95319677_179
Round3_nuclease_VEGFA_site2 chr7_130791581_10
Round3_nuclease_VEGFA_site2 chr8_144822961_728
Round3_nuclease_VEGFA_site2 chr8_145008405_603
Round3_nuclease_VEGFA_site2 chr9_103599649_1178
Round3_nuclease_VEGFA_site2 chr9_131706582_25
Round3_nuclease_VEGFA_site2 chr10_102821517_32
Round3_nuclease_VEGFA_site2 chr10_133956644_126
Round3_nuclease_VEGFA_site2 chr10_135149947_446
Round3_nuclease_VEGFA_site2 chr11_12308933_121
Round3_nuclease_VEGFA_site2 chr11_13948370_246
Round3_nuclease_VEGFA_site2 chr11_31817483_483
Round3_nuclease_VEGFA_site2 chr11_63391090_362
Round3_nuclease_VEGFA_site2 chr11_71948805_919
Round3_nuclease_VEGFA_site2 chr12_26025095_123
Round3_nuclease_VEGFA_site2 chr15_33286107_391
Deletions Read Count
Insertions Read Count
Base Position



Round3_nuclease_VEGFA_site2 chr15_78857725_24
Round3_nuclease_VEGFA_site2 chr16_57974238_30
Round3_nuclease_VEGFA_site2 chr17_4358752_803
Round3_nuclease_VEGFA_site2 chr17_16954852_141
Round3_nuclease_VEGFA_site2 chr17_40044757_791
Round3_nuclease_VEGFA_site2 chr17_46103848_21
Round3_nuclease_VEGFA_site2 chr17_55740529_31
Round3_nuclease_VEGFA_site2 chr18_21359559_357
Round3_nuclease_VEGFA_site2 chr19_13122188_291
Round3_nuclease_VEGFA_site2 chr19_14142975_192
Round3_nuclease_VEGFA_site2 chr19_18131314_4
Round3_nuclease_VEGFA_site2 chr19_45952054_74
Round3_nuclease_VEGFA_site2 chr22_40102400_36
Round3_nuclease_VEGFA_site2 chr22_43684495_25
Round3_nuclease_VEGFA_site2 chr22_47511254_52
Round3_nuclease_VEGFA_site2 chrX_129040641_263
Round3_nuclease_VEGFA_site2 chrX_152837128_37
Round3_nuclease_VEGFA_site3 chr2_73317048_122
Round3_nuclease_VEGFA_site3 chr3_71632809_215
Round3_nuclease_VEGFA_site3 chr4_58326607_97
Round3_nuclease_VEGFA_site3 chr5_29367379_103
Round3_nuclease_VEGFA_site3 chr5_115434675_2200
Round3_nuclease_VEGFA_site3 chr7_51294278_17
Round3_nuclease_VEGFA_site3 chr9_23824554_643
Round3_nuclease_VEGFA_site3 chr10_98760588_1437
Round3_nuclease_VEGFA_site3 chr11_68851138_1535
Round3_nuclease_VEGFA_site3 chr11_79178522_32
Round3_nuclease_VEGFA_site3 chr13_114882999_83
Round3_nuclease_VEGFA_site3 chr14_74353496_790
Round3_nuclease_VEGFA_site3 chr16_80016330_50
Round3_nuclease_VEGFA_site3 chr18_74103174_33
Round3_nuclease_VEGFA_site3 chr19_40561867_796



Deletions are shown above the X-axis whereas insertions are shown below. Boundaries of the overall target site (i.e., protospacer and PAM sequence) are shown with dotted lines and the boundary between the protospacer and PAM sequence is shown as a dotted line between the other two. RGN cleavage is predicted to occur 3 to 4 bps from the 5' edge of the PAM sequence.

Supplementary Fig. 5 Multi-factor linear regression model to show independent effects of factors on GUIDE-Seq read count



Nature Biotechnology: doi:10.1038/nbt.3117

Supplementary Fig. 6 Histogram plots of mapped indel mutations for seven ChIP-Seq binding sites previously characterized as off-target cleavage sites






sgRNA4-OT_478: chr14 97878369 - 97878491
WT Cas9+sgRNA
WT Cas9 only
Deletions Read Count
Insertions Read Count
Base Position
0
200
400
600
800
0
20
40
60
80
100
120


sgRNA4-OT_466: chr17 47299471 - 47299593
WT Cas9+sgRNA
WT Cas9 only
Deletions Read Count
Insertions Read Count
Base Position
0
100
200
300
0
20
40
60
80
100
120


sgRNA4-OT_481: chr10 72900946 - 72901068
WT Cas9+sgRNA
WT Cas9 only
Deletions Read Count
Insertions Read Count
Base Position
150
100
50
0
50
100
150
0
20
40
60
80
100
120


sgRNA4-OT_461: chr14 60207832 - 60207954
WT Cas9+sgRNA
WT Cas9 only
Deletions Read Count
Insertions Read Count
Base Position
300
200
100
0
100
200
300
0
20
40
60
80
100
120



Experimental and control samples are shown side-by-side for each site. Indels and target sites are plotted as in Supplementary Fig. 4.

Supplementary Fig. 7 GUIDE-Seq-based identification of DSBs induced by RGNs directed by tru-gRNAs





Start sites of GUIDE-Seq reads mapped back to the genome enable localization of the DSB to within a few base pairs. Mapped reads for the on- and off-target sites of the three RGNs directed by truncated gRNAs we assessed by GUIDE-Seq are shown. In all cases, the target site sequence is shown with the protospacer sequence to the left and the PAM sequence to the right on the x-axis.

Supplementary Table 1 Target Sites and Cell Lines Used

Target site name	Cells	Target Site (5' → 3')
EMX1	U2OS	GAGTCCGAGCAGAAGAAGAANGG
VEGFA site1	U2OS	GGGTGGGGGGAGTTTGCTCCNGG
VEGFA site2	U2OS	GACCCCCTCCACCCCGCCTCNGG
VEGFA site3	U2OS	GGTGAGTGAGTGTGTGCGTGNGG
RNF2	U2OS	GTCATCTTAGTCATTACCTGNGG
FANCF	U2OS	GGAATCCCTTCTGCAGCACCNGG
HEK293 site 1	293	GGGAAAGACCCAGCATCCGTNGG
HEK293 site 2	293	GAACACAAAGCATAGACTGCNGG
HEK293 site 3	293	GGCCCAGACTGAGCACGTGANGG
HEK293 site 4	293	GGCACTGCGGCTGGAGGTGGNGG
truncated VEGFA site 1	U2OS	GTGGGGGGAGTTTGCTCCNGG
truncated VEGFA site 3	U2OS	GAGTGAGTGTGTGCGTGNGG
truncated EMX1	U2OS	GTCCGAGCAGAAGAAGAANGG

Supplementary Table 2 Genomic locations of all GUIDE-Seq detected RGN-induced cleavage sites

See attached Excel file.

Supplementary Table 3 Summary of RGN-Independent Breakpoint Hotspots in Human U2OS and HEK293 Cells

Cells	Chromosome	Start	End	Interval (bp)
U2OS	chr1	121484547	121485429	882
U2OS	chr1	236260170	236260754	584
U2OS	chr3	197900267	197900348	81
U2OS	chr4	191044096	191044100	4
U2OS	chr5	10020	10477	457
U2OS	chr7	16437577	16439376	1799
U2OS	chr7	158129486	158129491	5
U2OS	chr9	140249964	140249977	13
U2OS	chr9	140610510	140610516	6
U2OS	chr10	42599569	42599575	6
U2OS	chr11	129573467	129573469	2
U2OS	chr11	134946499	134946506	7
U2OS	chr12	95427	95683	256
U2OS	chr12	29944278	29946544	2266
U2OS	chr16	83984266	83984271	5
U2OS	chr17	63965908	63967122	1214
U2OS	chr18	63765	63769	4
U2OS	chr18	37381409	37381971	562
U2OS	chr2	9877829	9877857	28
U2OS	chr2	182140586	182140587	1
U2OS	chr2	209041635	209041637	2
U2OS	chr2	242838677	242838859	182
U2OS	chr22	49779897	49782342	2445
U2OS	chr22	49780337	49780338	1
U2OS	chrX	155260204	155260352	148
HEK293	chr1	121484526	121485404	878
HEK293	chr6	58778207	58779300	1093
HEK293	chr7	61968971	61969378	407
HEK293	chr10	42385171	42385189	18
HEK293	chr10	42400389	42400394	5
HEK293	chr10	42597212	42599582	2370
HEK293	chr19	27731978	27731991	13

Supplementary Table 4 Common Primers Needed for GUIDE-Seq

P7 Adapters	Sequence (5' → 3')
P701	CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P702	CAAGCAGAAGACGGCATACGAGATCTAGTACGGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P703	CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P704	CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P705	CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P706	CAAGCAGAAGACGGCATACGAGATCATGCCTAGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P707	CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P708	CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTGACTGGAGTCCTCTCTATGGGCAGTCGGTGA
P5 Adapter Primers	**Sequence (5' → 3')**
P5_1	AATGATACGGCGACCACCGAGATCTA
P5_2	AATGATACGGCGACCACCGAGATCTACAC
Custom Sequencing Primers	**Sequence (5' → 3')**
Index1	ATCACCGACTGCCCATAGAGAGGACTCCAGTCAC
Read2	GTGACTGGAGTCCTCTCTATGGGCAGTCGGTGAT
Illumina Y-adapters 1-16 (with Molecular Index tag NNWNNWNN)	**Sequence (5' → 3')**
Miseq Common Adapter	[Phos]GATCGGAAGAGC*C*A
A01	AATGATACGGCGACCACCGAGATCTACACTAGATCGCNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A02	AATGATACGGCGACCACCGAGATCTACACCTCTCTATNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A03	AATGATACGGCGACCACCGAGATCTACACTATCCTCTNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A04	AATGATACGGCGACCACCGAGATCTACACAGAGTAGANNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A05	AATGATACGGCGACCACCGAGATCTACACGTAAGGAGNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A06	AATGATACGGCGACCACCGAGATCTACACACTGCATANNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A07	AATGATACGGCGACCACCGAGATCTACACAAGGAGTANNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A08	AATGATACGGCGACCACCGAGATCTACACCTAAGCCTNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A09	AATGATACGGCGACCACCGAGATCTACACGACATTGTNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A10	AATGATACGGCGACCACCGAGATCTACACACTGATGGNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A11	AATGATACGGCGACCACCGAGATCTACACGTACCTAGNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A12	AATGATACGGCGACCACCGAGATCTACACCAGAGCTANNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T

Illumina Y-adapters 1-16 (with Molecular Index tag NNWNNWNN)	Sequence (5' → 3')
A13	AATGATACGGCGACCACCGAGATCTACACCATAGTGANNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A14	AATGATACGGCGACCACCGAGATCTACACTACCTAGTNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A15	AATGATACGGCGACCACCGAGATCTACACCGCGATATNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T
A16	AATGATACGGCGACCACCGAGATCTACACTGGATTGTNNWNNWNNACACTCTTTCCCTACACGACGCTCTTCCGATC*T

*** Indicates a Phosphorothioate Bond Modification**

Primer Name	Sequence (5' → 3')	Strand/Direction
Nuclease_off_+_GSP1	GGATCTCGACGCTCTCCCTATACCGTTATTAACATATGACA	+
Nuclease_off_-_GSP1	GGATCTCGACGCTCTCCCTGTTTAATTGAGTTGTCATATGTTAATAAC	-
Nuclease_off_+_GSP2	CCTCTCTATGGGCAGTCGGTGATACATATGACAACTCAATTAAAC	+
Nuclease_off_-_GSP2	CCTCTCTATGGGCAGTCGGTGATTTGAGTTGTCATATGTTAATAACGGTA	-

Supplementary Results

Our re-analysis of sequencing data from the previous study of Kuscu et al.[1] suggested that the vast majority of indel mutations found at those sites were more likely caused by PCR or sequencing errors rather than by RGN cleavage activity. Kuscu et al. performed genome-wide ChIP-Seq on cells expressing dCas9 and a gRNA they refer to as sgRNA4. sgRNA 4 is the same as the gRNA we use in our current study that targets what we call HEK293 site 4. Kuscu et al. identified seven ChIP-Seq binding sites at which they reported that active Cas9 directed by sgRNA4 could induce indel mutations. Based on their observations, they concluded that these seven sites represent *bona fide* off-target Cas9 cleavage sites for sgRNA4.

However, our independent re-analysis of the Kuscu et al. data strongly suggests that the indel mutations they observed are unlikely to have been induced by Cas9 and sgRNA4. For many of the sites with statistically significant differences (FDR < 0.05) in indel percentages between their control and Cas9/sgRNA4 samples, the distribution of indels is not consistent with a Cas9-induced cleavage event (**Supplementary Fig. 6**). Cas9-mediated cleavage would be expected to introduce indels that primarily localize within 3 to 4 bps of the 5' edge of the PAM sequence. However, for nearly all of the seven sites, many of the indels localize to other parts of the protospacer. Examination of the protospacer sequences suggests that the observed indels may arise due the presence of homopolymer stretches, a known artifact with the Illumina next-generation sequencing platform. In addition, the patterns of indels at all seven of these sites are nearly identical between the control and the nuclease samples, again consistent with the idea that these indels are largely, if not wholly, sequencing artifacts. We conclude that it is unlikely that these seven sites represent *bona fide* Cas9/sgRNA4 cleavage sites.

1. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. *Nat Biotechnol* **32**, 677-683 (2014).

Supplementary Discussion

Potential reasons for failure to detect two previously described off-target sites of tru-gRNA-directed RGNs

One of the two tru-gRNA off-target sites not detected by GUIDE-Seq showed evidence of capture in our raw data but was filtered out by our read calling algorithm because the sequencing reads were only unidirectional and originated from just one primer (**Online Methods**). (The lack of bidirectional mapping reads for this site might be due to a repetitive region on one side of the off-target site that makes it challenging to map the reads accurately.) The other undetected tru-gRNA off-target site has been previously reported to be mutagenized at a low frequency and therefore it is possible that it was not detected in our experiment due to insufficient sampling of sequences.

Supplementary Methods – Detailed GUIDE-seq Protocol

Store at Room Temperature

Item	Vendor
Covaris S220 microTube,	Covaris
Ethanol, 200-proof (100%)	Sigma Aldrich
MicroAmp Optical 96-well Plates	Applied Biosystems
Nuclease-free H_2O	Promega
Qubit Assay Tubes, 500 tubes/pack	Invitrogen
Qubit dsDNA BR Kit – 500 Assays	Invitrogen
TMAC Buffer, 5M	Sigma Aldrich
-Tetramethylammonium Chloride	
1X TE Buffer/10mM Tris-HCl, pH 8.0	Invitrogen
UltraPure 0.5M EDTA, pH 8.0 (Gibco) (4x100 mL)	Life Technologies

Store at 4°C

Item	Vendor
Agencourt AMPure XP Beads- 60 mL	Beckman Coulter

Store at -20°C

Item	Catalog #
25mM dNTP Solution Mix	Enzymatics, Inc.
Slow ligation buffer	Enzymatics, Inc.
End-repair mix (low concentration)	Enzymatics, Inc.
T4 DNA Ligase	Enzymatics, Inc.
- 10X T4 DNA Ligase Buffer (Slow Ligation Buffer)	
Platinum® Taq DNA Polymerase	Life Technologies
-10X PCR Buffer (no $MgCl_2$)	
- 50mM $MgCl_2$	
qPCR Illumina Library Quantification Kits	KAPA Biosystems, Inc.

Equipment

96-well Plate Magnetic Stand	Invitrogen
Qubit Fluorometer 2.0	Life Technologies
Covaris S-2 Focused Ultra-sonicator™ Instrument	Covaris
Tabletop centrifuge	Thermo Scientific
Tabletop vortexer	Thermo Scientific
Thermocycler	Eppendorf
Miseq	Illumina

Protocol for GUIDE-seq Library Preparation

Y-adapter Preparation

The Y-adapter is made by annealing the Miseq common oligo with each of the sample barcode adapters (A01 to A16, see **Supplementary Table 4**). The adapters also contain 8-mer NN**W**NN**W**NN (N = A, C, T, or G; W = A or T) molecular indexes.

1X TE Buffer	80.0 µL
A## (100µM)	10.0 µL
MiSeq Common Adapter_MI (100µM)	10.0 µL
Total	**100.0 µL**

Annealing program: 95°C for 1 s; 60°C for 1s; slow ramp down (approximately -2°C/min) to 4°C; hold at 4°C. Store in -20°C.

Input Quantification and Shearing

1. dsDNA is quantified by Qubit and 400 ng is brought to a final volume of 120 ul using 1X TE Buffer.

2. Each sample is sheared to an average length of 500 bp according to the standard operating protocol for the Covaris S2.

3. A cleanup with 120 ul of AMPure XP SPRI beads (1X ratio) is performed according to manufacturer protocol, and eluted in 15 ul of 1X TE Buffer.

End repair, A-tailing and Ligation

End Repair

4. To a 200 µL PCR tube or well in a 96-well plate, add the following (per reaction):

Nuclease-free H_2O	0.5 µL
dNTP mix, 5mM	1.0 µL
SLOW Ligation Buffer, 10X	2.5 µL
End-repair mix (low concentration)	2.0 µL
Buffer for Taq Polymerase, 10X (Mg2 + free)	2.0 µL
Taq Polymerase (non-hot start)	0.5 µL
Total	**8.5 µL**
+ DNA sample (from previous step)	14.0 µL
Total	**22.5 µL**

End Repair Thermocycler Program: 12°C for 15min, 37°C for 15min; 72°C for 15min; hold at 4°C

Adapter Ligation

5. To the sample reaction tube or well, add the following reagents *in order* (mix by pipetting):

Reagent	Volume
Annealed Y adapter_MI (10µM)	1.0 µL
T4 DNA Ligase	2.0 µL
+ DNA sample (from previous step)	22.5 µL
Total	**25.5 µL**

Adapter Ligation Thermocycler Program: 16°C for 30min, 22°C for 30min, hold at 4°C

6. 0.9X SPRI clean (22.95 ul Ampure XP beads), elute in 12 uL of 1X TE buffer.

PCRs

PCR 1 (oligo tag primer [Discovery] or large primer pool [Deep-sequencing Validation])

7. Prepare the following master mix:

Reagent	Volume
Nuclease-free H_2O	11.9 µL
Buffer for Taq Polymerase, 10X ($MgCl_2$ free)	3.0 µL
dNTP mix, 10mM	0.6 µL
$MgCl_2$, 50 mM	1.2 µL
Platinum Taq polymerase, 5 U/µl	0.3 µL
GSP1 Primer (10uM)/Primer Pool (*)	1.0 µL*
TMAC (0.5M)	1.5 µL
P5_1, 10 µM	0.5 µL
Total	**20.0 µL**
+ DNA sample (from Step 6)	10.0 µL
Total	**30.0 µL**

* For Discovery, make separate master mixes for +/(sense) and –/(antisense) reactions, and proceed with separate PCR reactions.

* For deep-sequencing validation, one master mix can be made. Primer Pool should be normalized to a total amount of 30 pmol in the 30 ul reaction.

Discovery Thermocycler Program (touchdown):
95°C for 5 min,
15 cycles of [95°C for 30 s, 70°C (-1°C/cycle) for 2 min, 72°C for 30 s],
10 cycles of [95°C for 30 s, 55°C for 1 min, 72°C for 30 s],
72°C for 5 min,
4°C hold

Validation Thermocycler Program:
95°C for 5 min,
14 cycles of [95°C for 30 s, 20% ramping down to 65°C, 65°C for 5 min],
72°C for 5 min,
4°C hold

8. 1.2X SPRI clean (36.0 uL), elute in 15 ul of 1X TE Buffer.

PCR 2 (oligo tag primer [Discovery] or large primer pool [Deep-sequencing Validation])

9. Prepare the following master mix:

Nuclease-free H_2O	5.4 µL
Buffer for Taq Polymerase, 10X (Mg^{2+} free)	3.0 µL
dNTP mix, 10mM	0.6 µL
$MgCl_2$, 50 mM	1.2 µL
Platinum Taq polymerase, 5 U/µl	0.3 µL
GSP2 Primer (10uM)/Primer Pool (*)	1.0 µL
TMAC (0.5M)	1.5 µL
P5_2, 10 µM	0.5 µL
Total	**13.5 µL**
+ P7_# (10uM)*	1.5 µL
+ DNA sample with beads (from Step 8)	15.0 µL
Total	**30.0 µL**

* Primer concentrations should follow the specifications described in PCR1
* For the P7_#, at least 4 should be used in one sequencing run for good image registration on Illumina sequencer (e.g. P701 – P704 or P705 – P708)

Discovery Thermocycler Program (touchdown):
same as for PCR1

Validation Thermocycler Program:
same as for PCR1

10. 0.7X SPRI clean (21.0 uL), elute in 30 ul of 1X TE Buffer.

Library quantification by qPCR and Sequencing

qPCR Quantification

11. Quantitate library using Kapa Biosystems kit for Illumina Library Quantification kit, according to manufacturer instruction.

Normalization and Sequencing

12. Using the mean quantity estimate of number of molecules per uL given by the qPCR run for each sample, proceed to normalize the total set of libraries to 1.2 X 10^10 molecules, divided by the number of libraries to be pooled together for sequencing. This will give a by molecule input for each sample, and also a by volume input for each sample.

After pooling, Speedvac (dry down) the library with a Vacufuge to a final volume of 10 uL for sequencing.

Denature the library and load onto the Miseq according to Illumina's standard protocol for sequencing with an Illumina Miseq Reagent Kit V2 - 300 cycle (2 x 150 bp paired end), except:

1) Add 3 ul of 100 µM custom sequencing primer Index 1 to Miseq Reagent cartridge position 13 (Index Primer Mix). Add 3 ul of 100 µM custom sequencing primer Read 2 to Miseq Reagent cartridge position 14 (Read 2 Primer Mix).
2) Sequence with the following number of cycles "151 | 8 | 16 | 151" with the paired-end Nextera sequencing protocol.

Submit sequencing data in either bcl or fastq format to relevant pipelines for downstream bioinformatics analysis.